COVID-19 - Pipeline Analysis - Drug Development Strategies by Therapy, RoA, Target, Mechanism of Action, and Therapeutic Modalities

This pipeline analysis report provides detailed insights into the clinical trials landscape of COVID-19 therapeutics, including molecules at pre-clinical and discovery stage. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as therapy, route of administration (RoA), target, mechanism of action (MoA), and therapeutic modalities. Furthermore, the report provides an analysis of the companies currently involved in the development of pipeline molecules for COVID-19 including AbbVie Inc., AIM ImmunoTech Inc., Ansun BioPharma, APEIRON Biologics AG, Ascletis Pharma Inc., Blade Therapeutics Inc., Can-Fite BioPharma Ltd., CanSino Biologics Inc., Clover Biopharmaceuticals, F. Hoffmann-La Roche Ltd., FUJIFILM Corp., Gilead Sciences Inc., IMV Inc., InflaRx GmbH, Inovio Pharmaceuticals Inc., and Johnson & Johnson Services Inc.

Overview of Therapeutic Pipeline for COVID-19

The COVID-19 pandemic started in China in the last quarter of 2019 and spread globally by early 2020. Globally, the incidence and prevalence of COVID-19 are increasing aggressively. According to the Worldometers.info report, updated on April 13, 2020, the number of COVID-19 cases reported was 1,862,254, out of which 6.17% of the people have lost their lives, and about 23.18% people have been recovered globally.

Coronavirus disease (COVID-19) is infectious and is caused by a new coronavirus strain, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Most of the people affected with COVID-19 experience mild-to-moderate respiratory illness and recover without requiring special treatment. However, older people and people with certain medical conditions, including cardiovascular diseases, diabetes, chronic respiratory disease, and cancer, are more likely to develop serious illness. Currently, there are no specific vaccines or treatments for COVID-19. However, owing to the above-mentioned factors, many ongoing clinical trials are evaluating potential treatments, especially target molecules for the immune system. Over 26% of the molecules in the pipeline are currently in the pre-clinical stages.

Companies covered

Several companies are involved in the development of pipeline molecules for COVID-19. In addition to the companies, major institutes, universities, and hospitals are also conducting studies on COVID-19. Moreover, companies are collaborating with institutions such as the US Department of Health & Human Services and the University of British Columbia to use the available technologies properly for the further development and commercialization of molecules.

The report covers detailed information on several companies actively involved in the development of molecules for COVID-19 including -  

• AbbVie Inc.
• AIM ImmunoTech Inc.
• Ansun BioPharma
• APEIRON Biologics AG
• Ascletis Pharma Inc.
• Blade Therapeutics Inc.
• Can-Fite BioPharma Ltd.
• CanSino Biologics Inc.
• Clover Biopharmaceuticals
• F. Hoffmann-La Roche Ltd.
• FUJIFILM Corp.
• Gilead Sciences Inc.
• IMV Inc.
• InflaRx GmbH
• Inovio Pharmaceuticals Inc.
• Johnson & Johnson Services Inc.
• Mallinckrodt Plc
• Moderna Inc.
• NeuroRx Inc.
• Novavax Inc.
• OncoImmune Inc.
• OyaGen Inc.
• Pulmotect Inc.
• RedHill Biopharma Ltd.
• Regeneron Pharmaceuticals Inc.
• Sanofi
• SLA Pharma AG
• Sorrento Therapeutics Inc.
• Swedish Orphan Biovitrum AB
• Symvivo Corp.
• Takeda Pharmaceutical Co.
• Tonix Pharmaceuticals Holding Corp.
• Vanda Pharmaceuticals Inc.
• Vaxart Inc.

COVID-19 - Pipeline Analysis: Therapeutic Assessment of the Molecules for COVID-19 by Route of Administration

• Oral
• Intravenous
• Nasal
• Intradermal
• Intramuscular
• Unknown

Most of the pipeline molecules for COVID-19 treatment are being developed for oral administration. Additionally, companies and institutions are also focusing on developing drugs that can be delivered through the subcutis (intravenous RoA).

COVID-19 - Pipeline Analysis: Therapeutic Assessment of the Molecules for COVID-19 by Therapy

• Monotherapy
• Combination therapy

Monotherapy uses a single drug to treat a disorder. Over 64% of the molecules that are currently in the pipeline to treat COVID-19 are being developed as monotherapy drugs.

COVID-19 - Pipeline Analysis: Key Highlights of the Report

• What are the therapy molecules used in the various development stages of COVID-19?
• What are the companies that are currently involved in the development of therapeutic molecules for COVID-19?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

We can help! Our analysts can customize this report to meet your requirements. Get in touch